Elevated First-Trimester Total Bile Acid is Associated with the Risk of Subsequent Gestational Diabetes

Wolin Hou1, Xiyan Meng2, Weijing Zhao1, Jiemin Pan1, Junling Tang1, Yajuan Huan2, Minfang Tao2, Fang Liu1 & Weiping Jia1

The aim of the current study is to assess whether total bile acid (TBA) level in first trimester pregnancy is associated with gestational diabetes mellitus (GDM). Biochemical parameters including serum TBA of 742 pregnant women were collected within 12 weeks of gestation and compared. At 24–28th weeks of gestation, 75 g oral glucose tolerance test (OGTT) was performed. The perinatal data of 330 women were collected. The results demonstrated women with GDM (n = 268) had higher first-trimester serum levels of TBA compared with healthy subjects (n = 474) (2.3 ± 1.4 μmol/L vs. 1.9 ± 1.0 μmol/L, P < 0.001). TBA was independently associated with GDM [adjusted odds ratio (AOR), 1.38; 95% confidence interval (CI), 1.18–1.61, P < 0.001]. Compared to the first category of TBA, women in the highest category had a marked increase in risk for GDM (AOR, 7.72; 95% CI, 3.22–18.50, P < 0.001). In conclusion, higher first-trimester TBA levels, even within normal range, may help indicate increased risk of GDM.

The incidence of gestational diabetes mellitus (GDM) is gradually increasing worldwide1, ranging from 3% to 14%. Furthermore, the occurrence in the cities of north China is as high as 9.3% in all pregnant women2. Hyperglycemia during pregnancy leads to latent harmful impact on mothers such as preeclampsia, increased caesarean rates, macrosomia, premature rupture of membrane (PROM) and the development of type 2 diabetes mellitus (T2DM)3. Strategies to prevent GDM have great potential to prevent or delay the onset of overt diabetes. Insulin resistance normally increases during pregnancy and resolves upon delivery4. GDM develops due to an insufficient adaptation to growing insulin requirements and often accompanies with obesity and other risk factors for adverse pregnancy outcomes5.

There were several proposed potential biomarkers reflecting increased hazard for GDM from previous researches. For instance, prepregnancy low adiponectin concentration, a marker of decreased insulin sensitivity and altered adipocyte endocrine function, may identify women at high risk for GDM6. Sridhar, S.B. et al. reported that γ-glutamyltransferase (γ-GT) measured before pregnancy may help to identify women at increased risk for subsequent GDM7. In a large prospective cohort study, researchers reported that elevated asalanine aminotransferase (ALT) levels in the first trimester can be used to identify high risk women for GDM8. Another large retrospective study showed that higher levels of fasting blood glucose in first trimester were associated with increased risk of GDM, cesarean section, and macrosomia9. A case-control study performed by Thadhani, R. et al. demonstrated maternal follistatin-like-3 (FSTL3) levels, an inhibitor of activin and myostatin involved in glucose homeostasis, are decreased in first trimester and associated with subsequent GDM10. Although treatment of GDM in the second and third trimester of pregnancy improves some adverse perinatal outcomes11,12, earlier detection of women at higher risk for GDM through biomarker measurement allows more time for diet, medication and exercise intervention.

Bile acids (BAs) include primary BAs and secondary BAs. Primary BAs including cholic acid (CA), chenodeoxycholic acid (CDCA) are produced from cholesterol in the liver. Most of them are conjugated with taurine and glycine, stored in the gallbladder, and secreted into the duodenum upon meal stimulation and digest lipids and...
liped-soluble vitamins. Some primary BAs are transformed into secondary BAs including deoxycholic acid (DCA) and lithocholic acid by gut microbiome. In recent years, BAs have been indicated as important regulatory molecules of whole-body metabolism, increasing energy expenditure and preventing obesity, insulin resistance, and T2DM by activating specific nuclear and cell surface receptors such as the farnesoid X receptor (FXR) and the G protein-coupled receptor (TGR5), respectively. Brufau, G. et al. reported that T2DM subjects had greater CA synthesis rates and enlarged DCA pool size. A recent study also found that BAs were nearly twofold elevated in T2DM patients compared with healthy subjects, and the disproportion in BAs was associated with insulin resistance. Although total bile acid (TBA) has been known to correlate with features of insulin resistance and the development of T2DM, and insulin resistance is considered as the main mechanism underlying the pathophysiology of GDM, the change of TBA level during pregnancy and its relationship with the risk of GDM remain unclear. Thus, the aim of the present study was to clarify whether TBA at early pregnant stage is associated with the development of GDM.

**Results**

**Subject characteristics.** In this nested case-control study, a total of 742 pregnant women [mean age 30.1 ± 3.8 years, mean prepregnancy body mass index (BMI) 22.7 ± 3.3 kg/m²] were enrolled in this study. The clinical characteristics of control and GDM patients are shown in Table 1. In women who developed GDM, the incidence of diabetes family history and multiparity history before pregnancy were significantly higher. There were significant differences in age, prepregnancy BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), glycosylated hemoglobin A1c (HbA1c), γ-glutamyl transferase (γ-GT), cholinesterase (ChE), TBA, triglyceride (TG), fasting insulin, 1- and 2-hour insulin values, fasting plasma glucose, 1- and 2-hour glucose levels, homeostasis model assessment of insulin resistance index (HOMA-IR) and homeostasis model assessment of β cell insulin secretion (HOMA-β) (all \(P < 0.05\)). One hundred and seventy nine women with GDM and 151 women without were followed up until delivery, their perinatal data are shown in Table 2. There were significant differences in age, prepregnancy BMI, SBP, DBP, TBA, ChE, and TG between the two groups. The incidence of caesarean section and macrosomia and infant birth weight were significantly higher in women with GDM than healthy pregnant women (caesarean section, 26.4% vs. 17.3%, \(P = 0.045\); macrosomia, 11.9% vs. 3.4%, \(P = 0.003\); infant birth weight, 3385.3 ± 489.9 g vs. 3279.4 ± 417.7 g, \(P = 0.035\)). Other adverse pregnancy outcomes such as preeclampsia and PROM showed no marked difference.

**Binary logistic regression analysis of the association of TBA with clinical variables and adverse pregnancy outcomes.** In order to find out which factors were independently associated with GDM and other adverse pregnancy outcomes, binary logistic regression was performed (Table 3). A significant independent association was found between serum TBA and GDM (OR, 1.31; 95% CI, 1.15–1.50, \(P < 0.001\)). BMI, SBP, ChE and TG were found to be related to GDM. In the macrosomia subgroup, TBA (OR, 1.53; 95% CI, 1.13–2.08, \(P = 0.006\)) and BMI (OR, 1.25; 95% CI, 1.11–1.40, \(P < 0.001\)) were independent risk factors. In the caesarean subgroup, only BMI was identified as an independent risk factor (OR, 1.13; 95% CI, 1.04–1.23, \(P = 0.004\)). In the preeclampsia subgroup, age (OR, 1.21; 95% CI, 1.01–1.44, \(P = 0.036\)) and ChE (OR, 1.02; 95% CI, 1.00–1.03, \(P = 0.016\)) were independent risk factors. No significant correlation between those clinical variables and PROM was found. After adjustment for age, BMI, SBP, DBP, TG, and other potential confounders, TBA was still an independent risk factor for GDM (OR, 1.38; 95% CI, 1.18–1.62, \(P < 0.001\)).

**The association between TBA and other clinical and biochemical characteristics at prenatal visit and delivery.** A Spearman’s correlation analysis showed that serum TBA level was positively associated with HOMA-IR (\(r = 0.08\)), HOMA-β (\(r = 0.08\)) and neonatal weight (\(r = 0.12\)) (all \(P < 0.05\)). Multiple stepwise regression analysis showed that age (\(β = −0.075, P = 0.041\)), BMI (\(β = 0.099, P = 0.007\)), 1-hour glucose level (\(β = 0.110, P = 0.003\)) and 2-hour glucose level (\(β = 0.145, P < 0.001\)) were independent risk factors for TBA in all pregnant women.

**Receiver operating characteristic (ROC) analysis of clinical variables for GDM.** ROC curve analysis revealed that area under curve (AUC) of serum TBA for indicating GDM was 0.569 (95% CI, 0.526–0.612; \(P = 0.002\)), AUC of age, prepregnancy BMI, SBP, DBP, ChE and TG to indicate GDM were 0.585 (95% CI, 0.542–0.628; \(P < 0.001\)), 0.546 (95% CI, 0.502–0.589; \(P = 0.039\)), 0.565 (95% CI, 0.522–0.608; \(P = 0.003\)), 0.566 (95% CI, 0.522–0.610; \(P = 0.003\)), 0.600 (95% CI, 0.558–0.643; \(P < 0.001\)) and 0.552 (95% CI, 0.509–0.595; \(P = 0.018\)).

**The occurrence and risk of GDM in different serum TBA categories.** TBA levels were analyzed in five categories: category 1 (<1.0 μmol/L, \(n = 71\)), category 2 (1.0–2.0 μmol/L, \(n = 354\)), category 3 (2.0–3.0 μmol/L, \(n = 188\)), category 4 (3.0–4.0 μmol/L, \(n = 76\)), category 5 (≥4.0 μmol/L, \(n = 53\)). The occurrence of GDM showed an increasing trend in the five categories (\(P < 0.001\)). Compared to the first category, the occurrence rates of GDM in the third and the fifth categories were significantly higher (37.8% vs. 23.9%, \(P = 0.024\); 64.2% vs. 23.9%, \(P < 0.001\), respectively) (Fig. 1). When considering TBA category 1 as the referent, women in the third and the fifth categories had markedly higher risk for GDM (OR, 1.93; 95% CI, 1.04–3.58, \(P = 0.038\); OR, 5.68; 95% CI, 2.60–12.43, \(P < 0.001\), respectively). After controlling for age, BMI and other confounders, the odds ratios for GDM were still significantly higher in category 3 (OR, 2.53; 95% CI, 1.29–4.99, \(P = 0.007\)) and category 5 (OR, 7.72; 95% CI, 3.22–18.50, \(P < 0.001\)) compared to category 1 (Fig. 2).

**Discussion**

In the present study, we confirmed the link of TBA concentration with GDM in Chinese pregnant women. First-trimester TBA levels in women who developed GDM later were significantly higher than healthy women.
GDM compared to the lowest category (TBA compared with non-pregnant women). Due to the insusceptible nature of TBA to pregnancy, elevated first trimester and were slightly increased, within the normal range, in the second and third trimester of pregnancy associated with HOMA-IR and GDM. It has been reported that BAs remained almost unchanged during the progress of T2DM and its relationship with insulin resistance. Cariou, B. et al. reported 1.6-fold increases in DCA (sum of CA, DCA, and their conjugates) compared to obese controls. Our colleagues recently reported the levels of CDCA in individuals with T2DM and HOMA-IR was positively related with CDCA, CA and DCA after adjustment for other confounders.

Higher first-trimester TBA levels within normal range were independently related with increased risk of GDM, other confounders. Similarly, obese subjects with T2DM have higher synthesis of 12-hydroxy BAs (sum of CA, CDCA, and their conjugates) compared to obese controls. In the present research, BAs, which was known to be related to the development of T2DM, was also relative to total BA (CDCA%) were significantly higher in obese individuals with T2DM than non-T2DM obese subjects.

Higher first-trimester TBA levels within normal range were independently related with increased risk of GDM, without a clear threshold. The highest category of TBA levels (TBA ≥ 4.0 μmol/L) reflected 6.72 increased risk for GDM compared to the lowest category (TBA < 1.0 μmol/L) after adjusting for age, BMI and other confounders.

Table 1. Comparison of clinical characteristics and biochemical indexes of GDM and healthy pregnant women. GDM, gestational diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; GA, gestational age; HbA1c, hemoglobin A1c; Abortion history, abortion history; Family history of diabetes, family history of diabetes; HOMA-IR, homeostasis model assessment of insulin resistance index; HOMA-β, homeostasis model assessment of beta cell insulin secretion. Data represent means ± SD or percentage (%). *Derived from Student's t-test. †Derived from Chi-square test or Fisher's Exact Test. ‡Derived from Mann-Whitney U-test. §Significant at P < 0.05 level.

| Group                                | Control          | GDM              | P value |
|--------------------------------------|------------------|------------------|---------|
| N                                    | 474              | 268              |         |
| Age (years)*                         | 29.8 ± 3.8       | 30.8 ± 3.8       | 0.001*  |
| Prepregnancy BMI (kg/m²)*            | 22.5 ± 3.3       | 23.1 ± 3.5       | 0.020*  |
| SBP (mm Hg)*                         | 110.4 ± 12.6     | 113.2 ± 13.1     | 0.004*  |
| DBP (mm Hg)*                         | 66.4 ± 9.4       | 68.6 ± 10.4      | 0.003*  |
| Family history of diabetes (%)*      | 0.4              | 2.2              | 0.026*  |
| Nulliparous (%)*                     | 77.8             | 72.0             | 0.046*  |
| Abortion history (%)                 | 31.2             | 37.3             | 0.054*  |
| GA (%)                               | 11.6 ± 1.4       | 11.7 ± 1.4       | 0.950*  |
| HbA1c (mmol/mol)*                    | 30.0 ± 3.1       | 32.0 ± 5.3       | < 0.001*|
| HbA1c (%)*                           | 4.9 ± 0.3        | 5.1 ± 0.7        | < 0.001*|
| ALT (U/L)*                           | 17.7 ± 11.9      | 19.2 ± 15.0      | 0.158*  |
| AST (U/L)*                           | 19.3 ± 6.9       | 19.4 ± 6.9       | 0.873*  |
| γ-GT (U/L)*                          | 15.2 ± 9.0       | 17.3 ± 11.2      | 0.006*  |
| ChE (U/L)*                           | 267.5 ± 49.8     | 285.4 ± 51.2     | < 0.001*|
| TBA (μmol/L)*                        | 1.9 ± 1.0        | 2.3 ± 1.4        | < 0.001*|
| TBil (μmol/L)*                       | 8.2 ± 2.8        | 8.1 ± 2.9        | 0.480*  |
| PAR (mg/L)*                          | 238.2 ± 42.2     | 243.4 ± 43.2     | 0.112*  |
| BUN (mmol/L)*                        | 2.7 ± 0.7        | 2.6 ± 0.6        | 0.278*  |
| Cr (μmol/L)*                         | 44.0 ± 6.0       | 43.2 ± 6.2       | 0.083*  |
| UA (μmol/L)*                         | 203.8 ± 44.2     | 209.9 ± 44.6     | 0.070*  |
| TC (mmol/L)*                         | 4.9 ± 0.9        | 4.9 ± 1.0        | 0.727*  |
| TG (mmol/L)*                         | 1.7 ± 1.0        | 1.9 ± 1.1        | 0.037*  |
| HDL-C (mmol/L)*                      | 1.8 ± 0.4        | 1.8 ± 0.4        | 0.072*  |
| LDL-C (mmol/L)*                      | 2.5 ± 0.7        | 2.5 ± 0.7        | 0.788*  |

75-gOGTT

|       | Control         | GDM              | P value |
|-------|-----------------|------------------|---------|
| Gestational age at OGTT (weeks) | 26.7 ± 1.4       | 26.7 ± 1.3       | 0.967*  |
| Insulin 0h (μU/ml)*             | 8.5 ± 4.2        | 11.1 ± 5.8       | < 0.001*|
| Insulin 1h (μU/ml)*             | 70.9 ± 40.7      | 89.4 ± 54.0      | < 0.001*|
| Insulin 2h (μU/ml)*             | 55.9 ± 37.1      | 91.1 ± 65.6      | < 0.001*|
| Glucose 0h (mmol/L)*            | 4.5 ± 0.3        | 5.0 ± 0.5        | < 0.001*|
| Glucose 1h (mmol/L)*            | 7.9 ± 1.2        | 9.8 ± 1.6        | < 0.001*|
| Glucose 2h (mmol/L)*            | 6.3 ± 1.2        | 8.2 ± 1.6        | < 0.001*|
| HOMA-IR*                        | 1.7 ± 0.9        | 2.5 ± 1.4        | < 0.001*|
| HOMA-β (%)*                     | 1.9 ± 1.4        | 1.7 ± 1.1        | 0.035*  |
First-trimester TBA level may reflect an underlying, more severe insulin resistance at early pregnancy stage in women who developed GDM.

Many of the beneficial effects of BAs on glucose metabolism are mediated via activating two receptors, FXR and TGR5. In vivo research showed FXR activation stimulates the insulin/Akt pathway in adipose tissue and skeletal muscle of mice, thus improving peripheral insulin sensitivity. Other animal studies found that bile acid sequestrants colesevelam and resin stimulated glucagon-like peptide-1 (GLP-1) release through activation of TGR5, resulting in alleviative insulin resistance in diet-induced obese mice. BA sequestrants, which block BA re-absorption in the gut and cause a compensatory increase in BA synthesis, are developed to treat hypercholesterolemia and improve glycemic status in T2DM. These findings suggested that up-regulated TBA concentration might be protective at the early stage of GDM in order to ameliorate insulin resistance. On the other hand, the synthesis of BA was dependent on glucose through the cholesterol pathway. Glucose supplied the substrates including acetyl-coenzyme A and nicotinamide adenine dinucleotide phosphate (NADPH) and energy required for cholesterol synthesis. In our study, postprandial glucose levels were independently correlated with TBA concentration. The increase in TBA might be a result of elevation of cholesterol production in liver following an increase in glucose supply. Besides, Gerhard, G.S. et al. hypothesized that an impairment in the enterohepatic

| Group | Control | GDM | P value |
|-------|---------|-----|---------|
| N     | 179 | 151 |         |
| Age (years) | 29.9 ± 3.7 | 31.2 ± 3.9 | 0.001† |
| Prepregnancy BMI (kg/m²) | 20.8 ± 2.9 | 22.5 ± 2.9 | <0.001* |
| SBP (mm Hg) | 110.3 ± 12.6 | 113.9 ± 11.8 | 0.008* |
| DBP (mm Hg) | 68.8 ± 9.7 | 69.3 ± 10.5 | 0.022* |
| TBA (μmol/L) | 1.6 ± 0.8 | 2.2 ± 1.3 | <0.001† |
| ChE (U/L) | 269.5 ± 47.3 | 250.5 ± 53.3 | <0.001* |
| UA (μmol/L) | 205.9 ± 43.6 | 210.2 ± 42.9 | 0.507† |
| TC (mmol/L) | 4.6 ± 1.0 | 4.6 ± 0.9 | 0.986* |
| TG (mmol/L) | 1.5 ± 1.2 | 1.7 ± 0.8 | 0.011† |
| Gestational age at delivery (weeks) | 38.9 ± 1.3 | 39.0 ± 1.3 | 0.453† |
| Caesarean section (%) | 17.3 | 26.4 | 0.045* |
| PROM (%) | 10 | 25.3 | 0.224* |
| Preeclampsia (%) | 2.8 | 2.6 | 0.605* |
| Amount of postpartum hemorrhage (ml) | 332.2 ± 117.2 | 326.0 ± 204.0 | 0.787† |
| AFI (cm) | 12.1 ± 3.2 | 12.4 ± 3.4 | 0.435† |

Table 2. Comparison of pregnancy outcomes of GDM and healthy pregnant women. GDM, gestational diabetes mellitus; BPD, biparietal diameter; PROM, premature rupture of membrane; AFI, amniotic fluid index. Data represent means ± SD or percentage (%). *Derived from Student’s t-test. †Derived from Chi-square test or Fisher’s Exact Test. #Derived from Mann-Whitney U-test. &Significant at P < 0.05 level.

| GDM | Macrosomia | Caesarean section | PROM | Preeclampsia |
|-----|------------|------------------|------|-------------|
| TBA | 1.31 (1.15–1.50)** | 1.53 (1.13–2.08)** | 1.10 (0.87–1.39) | 0.96 (0.70–1.32) | 0.84 (0.42–1.69) |
| Age | 1.07 (1.03–1.12)** | 1.00 (0.90–1.11) | 0.96 (0.90–1.03) | 1.02 (0.93–1.11) | 1.21 (1.01–1.44)* |
| BMI | 1.06 (1.01–1.10)* | 1.25 (1.11–1.40)*** | 1.13 (1.04–1.23)** | 1.08 (0.96–1.21) | 1.17 (0.97–1.40) |
| SBP | 1.02 (1.01–1.03)** | 1.02 (0.98–1.05) | 1.02 (1.00–1.04) | 1.01 (0.99–1.04) | 1.03 (0.98–1.08) |
| DBP | 1.02 (1.01–1.04)** | 0.98 (0.94–1.02) | 1.00 (0.98–1.03) | 1.00 (0.96–1.03) | 1.10 (1.02–1.15)* |
| ChE | 1.01 (1.00–1.01)*** | 1.00 (1.00–1.01) | 1.00 (0.99–1.00) | 1.00 (1.00–1.01) | 1.02 (1.00–1.03)* |
| TC | 0.97 (0.83–1.14) | 1.17 (0.77–1.77) | 0.95 (0.71–1.36) | 0.83 (0.59–1.18) | 1.22 (0.64–2.34) |
| TG | 1.17 (1.01–1.35)* | 1.26 (0.96–1.64) | 1.08 (0.85–1.35) | 1.24 (0.89–1.72) | 0.98 (0.50–1.93) |
| UA | 1.00 (1.00–1.01) | 1.00 (1.00–1.01) | 1.01 (1.00–1.01) | 1.00 (0.99–1.00) | 1.01 (1.00–1.02) |

Table 3. Binary logistic regression analysis of the association of first-trimester TBA with clinical variables and adverse pregnancy outcomes. GDM, gestational diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ChE, cholinesterase; TBA, total bile acid; UA, uric acid; TC, total cholesterol; TG, total triglycerides; PROM, premature rupture of membrane. *P < 0.05, **P < 0.01, ***P < 0.001.
circulation of BAs possibly present in diabetic state. Taken together, further studies are necessary to profoundly understand the underlying mechanism of TBA in the progress of GDM.

Maternal hyperglycemia less severe than overt diabetes is related to clinically important perinatal disorders such as macrosomia, primary cesarean delivery, premature delivery, neonatal hypoglycemia. In the present study, women in GDM group had significantly higher incidence of caesarean section and macrosomia. The development of GDM could be predicted from maternal age and prepregnancy BMI. Sridhar, S.B. et al. reported that pregravid -GT may help to identify women at increased risk for GDM. Another research indicated that elevated ALT levels in the first trimester can be used to identify high-risk women for subsequent GDM. In the current study, -GT levels among women who developed GDM were similarly higher than non-GDM women, but it was not found to be an independent risk factor for GDM. This result suggested that -GT levels, at least determined during pregnancy, was not associated with GDM. And in our research, ALT levels in GDM group were slightly elevated, but the difference did not reach statistical significance. The inconsistence of our results with previous study may be due to relatively small sample size.

Although first-trimester HbA1c levels were measured for preliminary screening of overt diabetes, we did not consider HbA1c as predictor of GDM. Firstly, hemoglobin (Hb) concentration fluctuated during pregnancy. Blood volume increases during pregnancy and the gradual increase in blood volume begins in the first trimester, so first-trimester hemoglobin levels may be decreased because of pregnancy. Thus, HbA1c may not truly reflect the glucose control during past 8–12 weeks in pregnant women. Secondly, HbA1c assay were not standardized in China. Thirdly, due to the disparities of HbA1c measuring methods and low quality control, HbA1c was not

Figure 1. The occurrence of GDM in different first-trimester TBA categories. TBA categories are defined as follows: category 1 (<1.0 μmol/L, n = 71), category 2 (1.0–2.0 μmol/L, n = 354), category 3 (2.0–3.0 μmol/L, n = 188), category 4 (3.0–4.0 μmol/L, n = 76), category 5 (≥4.0 μmol/L, n = 53). *P < 0.05, **P < 0.001 compared with the first TBA category. The overall P value was less than 0.001.

Figure 2. The risks for GDM in different first-trimester TBA categories. TBA categories are defined as follows: category 1 (<1.0 μmol/L, n = 71), category 2 (1.0–2.0 μmol/L, n = 354), category 3 (2.0–3.0 μmol/L, n = 188), category 4 (3.0–4.0 μmol/L, n = 76), category 5 (≥4.0 μmol/L, n = 53). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the corresponding TBA category 1 (referent). The overall P value was less than 0.05.
recommended as diagnostic criteria of diabetes according to the guideline of Chinese Diabetes Society (CDS), and was not suitable for diagnosing gestational diabetes mellitus. Thus, we did not focus on using HbA1c for early GDM detection.

There were some limitations of our study. Firstly, some other confounding factors of GDM such as diet and physical activity were not excluded. Secondly, we did not further test individual BAs and analyze their relationship with GDM. Moreover, serum TBA levels were measured only in a fasting state. Serum TBA can increase 4.5- to 6-fold during the first 30 minutes after a single oral glucose tolerance test. The profile of postprandial TBA after a standard diet may be considered as a better risk factor for GDM. Thirdly, the ethnicity of the study population was relatively monotonous as we only recruited pregnant women from Shanghai. A well-designed, population-based prospective study should be conducted to overcome these limitations.

In summary, based on the results above, we can draw the conclusions that serum TBA level in first-trimester pregnancy was independently associated with the subsequent occurrence of GDM, elevated plasma TBA level, even within the normal reference range, identified women at high risk for GDM. Moreover, because of the feasibility, simplicity and convenience of its assay, serum TBA level can be a potentially new biomarker distinguishing women at high and low risk for GDM at early pregnancy.

Methods

Subject. It was a nested case-control study of subjects enrolled in a prospective cohort of pregnant women. In brief, from January 2013 to August 2015, we set up a cohort of pregnant women who received prenatal care at the Department of Obstetrics and Gynecology of Shanghai Jiao-Tong University Affiliated Sixth People’s Hospital. Their clinical and biochemical profiles longitudinally were documented from antenatal visit to delivery. To clarify the association between first-trimester TBA levels and GDM, we conducted a nested case-control study. Diagnostic 75-g, 3-hour oral glucose tolerance test (OGTT) was performed at 24–28th weeks of gestation. GDM was diagnosed when one or more of the following plasma glucose values were met or exceeded: fasting, 5.1 mmol/L, 1 hour, 10.0 mmol/L, and 2 hours, 8.5 mmol/L, according to the criteria established by the International Association of Diabetes and Pregnancy Study Group (IADPSG). Women with alcohol consumption, preconceptional diabetes, intrahepatic cholestasis of pregnancy, chronic or serious acute infections, cardiovascular disease, hematomal diseases, severely impaired liver or kidney function or if they have been tested for positive hepatitis C antibodies or HIV were excluded. The study was approved by the Ethics Committee of the Shanghai Jiao-Tong University Affiliated Sixth People’s Hospital. The informed consents were completed by all the participants. The methods were performed in accordance with the Declaration of Helsinki.

Data collection. All the participants completed a questionnaire that collected general background information including present and previous illness, reproductive history, medication, alcohol consumption and smoking status. Height, weight and blood pressure were assessed on a standardized form by the same physician during the health check-up. BMI was calculated as BMI = body weight (in kg)/height (in m²). Macrosomia was defined as birth weight ≥4,000 g. Preeclampsia was defined according to new-onset hypertension and proteinuria, which appeared after 20 weeks of gestation. PROM was diagnosed when membranes ruptured before the onset of labor.

Laboratory measurements. Blood samples were drawn after an overnight fast within 12 weeks of gestation. All biochemical parameters including TBA were analyzed in the same serum sample. HbA1c was determined by high-pressure liquid chromatography and glycated serum albumin (GA) was measured by the liquid enzymatic assay, the linearity ranges were 3.5–20% and 5–60%. Serum TBA concentration was determined by enzymatic method using an automatic analyzer (7600-020 biochemistry automatic analyzer, Hitachi, Tokyo, Japan), the linearity range was 0–180 μmol/L, and the normal range was 0 to 10 μmol/L, the intra-assay and inter-assay coefficients of variation for TBA were less than 5% and 10%. Other biochemical indices evaluating hepatorenal function such ALT, aspartate aminotransferase (AST), γ-GT, ChE, blood urea nitrogen (BUN), creatinine (Cr), uric acid (UA) and serum lipids including TG, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) were performed by enzymatic method, the linearity ranges were 0–450 U/L, 0–450 U/L, 15–232 U/L, 0–11000 U/L, 0–43 mmol/L, 0–10000 μmol/L, 0–1500 μmol/L, 0–11.3 mmol/L, 0–20.68 mmol/L, 0–3.88 mmol/L, 0–12.9 mmol/L, respectively. Plasma glucose values were measured by glucose oxidase method, the linearity range was 0–35 mmol/L. Insulin concentrations were determined with a 2-site chemiluminescent enzyme immunoassay (Enzyme immunoassay for the immulite automated analyzer (Diagnostic Products, Los Angeles, CA), the linearity range was 0.02–1000 μU/ml. The intra-assay and inter-assay coefficients of variation for all biochemical indexes were less than 10%. The degree of insulin resistance was measured by HOMA-IR, calculated using the following formula: fasting glucose (mmol/l) × fasting insulin (μU/ml)/22.5. The HOMA-β was used for the assessment of insulin secretion, and it was calculated as [20 × fasting insulin (μU/ml)]/[fasting glucose (mmol/l)–3.5].

Statistical analysis. Data were expressed as mean ± standard deviation (SD) for continuous variables and percentages (%) for categorical variables. Differences between groups were evaluated with Student’s t test or Mann-Whitney U test for continuous variables and Chi-square test or Fisher’s exact test for categorical variables. The association between TBA and other characteristics at pregravid visit and delivery was evaluated with Spearman correlation and partial correlation analysis. Binary logistic regression analysis was performed to evaluate the odds ratios (OR) and 95% confidence intervals (CIs) in univariable and multivariable analysis. Multiple stepwise regression analysis was used to investigate the influence of different variables on TBA. All the statistical analysis was performed by SPSS 21.0 (SPSS Inc., Chicago, IL). A two-sided P < 0.05 was considered statistically significant.
References

1. Metzger, B. E. et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes care* **33**, 676–682 (2010).
2. Chang, Y., Chen, X., Cui, H., Zhang, Z. & Cheng, L. Follow-up of postpartum women with gestational diabetes mellitus (GDM). *Diabetes Res Clin Pract* **106**, 236–240 (2014).
3. Metzger, B. E. et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* **358**, 1991–2002 (2008).
4. Ryan, E. A., O’Sullivan, M. J. & Skyler, J. S. Insulin action during pregnancy. Studies with the euglycemic clamp technique. *Diabetes* **34**, 380–389 (1985).
5. Buchanan, T. A., Xiang, A., Kjos, S. L. & Watanabe, R. What is gestational diabetes? *Diabetes care* **30** Suppl 2, S105–S111 (2007).
6. Heddens, M. M. et al. Low prepregnancy adiponectin concentrations are associated with a marked increase in risk for development of gestational diabetes mellitus. *Diabetes care* **36**, 3930–3937 (2013).
7. Sridhar, S. B. et al. Pregravid liver enzyme levels and risk of gestational diabetes mellitus during a subsequent pregnancy. *Diabetes care* **37**, 1878–1884 (2014).
8. Leng, J. et al. Plasma Levels of Alanine Aminotransferase in the First Trimester Identify High Risk Chinese Women for Gestational Diabetes. *Sci Rep* **6**, 27291 (2016).
9. Raskin-Mashiah, S., Younes, G., Damti, A. & Auslender, R. First-trimester fasting hyperglycemia and adverse pregnancy outcomes. *Diabetes Care* **32**, 1639–1643 (2009).
10. Thadhani, R. et al. First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus. *Diabetes Care* **33**, 664–669 (2010).
11. Landon, M. B. et al. A multicenter, randomized trial of treatment for mild gestational diabetes. *N Engl J Med* **361**, 1339–1348 (2009).
12. Crowther, C. A. et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med* **352**, 2477–2486 (2005).
13. Cato, A. F., Parvu, A., Muresan, A. & Busetto, L. Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from Bariatric/Metabolic Surgery. *Obes Facts* **8**, 350–363 (2015).
14. Hylemon, P. B. et al. Bile acids as regulatory molecules. *J Lipid Res* **50**, 1509–1520 (2009).
15. Steels, B. & Fonseca, V. A. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. *Diabetes care* **32** Suppl 2, S237–S245 (2009).
16. Bruuau, G. et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. *Hepatology* **52**, 1455–1464 (2010).
17. Haesler, R. A., Astiarraga, B., Camastra, S., Accili, D. & Ferrannini, E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. *Diabetes* **62**, 4184–4191 (2013).
18. Cariou, B. et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. *Nutr Metab (Lond)* **8**, 48 (2011).
19. Ferrannini, E. et al. Increased Bile Acid Synthesis and Decomposition After Biliopancreatic Diversion. *Diabetes* **64**, 3377–3385 (2015).
20. Yu, H. et al. Chenodeoxycholic Acid as a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese Patients. *J Clin Endocrinol Metab* **100**, 4222–4230 (2015).
21. Jamjute, P., Ahmad, A., Ghosh, T. & Banfield, P. Liver function test and pregnancy. *J Matern Fetal Neonatal Med* **27**, 274–283 (2009).
22. Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. *J Biol Chem* **281**, 11039–11049 (2006).
23. Pothoff, M. J. et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. *Am J Physiol Gastrointest Liver Physiol* **304**, 371–380 (2013).
24. Harach, T. et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. *Sci Rep* **2**, 430 (2012).
25. Handelsman, Y. et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. *Endocr Pract* **16**, 617–628 (2010).
26. Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E. & Jones, M. R. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. *Diabetes care* **31**, 1479–1484 (2008).
27. Yamakawa, T., Takano, T., Utsunomiya, H., Kadonosono, K. & Okamura, A. Effect of colestipol therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. *Endocr J* **54**, 53–58 (2007).
28. Hışmışgullari, A. A., Bozdai, A. M. & Rahman, K. Biliary lipid secretion. *Turk J Gastroenterol* **18**, 65–70 (2007).
29. Gerhard, G. S. et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. *Diabetes care* **36**, 1859–1864 (2013).
30. Crowther, C. A. et al. Effect of treatment of gestational diabetson pregnancy outcomes. *N Engl J Med* **352**, 2477–2486 (2005).
31. van Leeuwen, M. et al. Estimating the risk of gestational diabetes mellitus: a clinical prediction model based on patient characteristics and medical history. *Biol Reprod* **78**, 69–75 (2008).
32. Scott, D. E. Anemia during pregnancy. *Obstet Gynecol Ann* **1**, 219 (1972).
33. Zhao, X. et al. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? *Am J Physiol Endocrinol Metab* **296**, E384–E393 (2009).
34. American Diabetes Association. Standards of medical care in diabetes—2013. *Diabetes care* **36** Suppl 1, S11–S66 (2013).

Acknowledgements
This work was supported by the grants from National Science Foundation of China (81270397 for Fang Liu) and Shanghai Science & Technology Pillar Program in the Field of Medicine and Agriculture (15411953100 to Fang Liu).

Author Contributions
F.L. designed the study, W.H. and X.M. contributed to data analysis and W.H. drafted the manuscript. F.L., Y.H. and W.J. reviewed and edited the manuscript. J.T. measured biochemical indexes, W.Z., J.P. and M.T. collected all the sample and clinical data and took the responsibility of data integrity. All authors reviewed the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Hou, W. et al. Elevated First-Trimester Total Bile Acid is Associated with the Risk of Subsequent Gestational Diabetes. *Sci. Rep.* **6**, 34070; doi: 10.1038/srep34070 (2016).
